Company Snapshot
| Field | Value |
|---|---|
| Company | Cooper Companies |
| Security line(s) | COO |
| SEC CIK | 711404 |
| GICS sector | Health Care |
| GICS sub-industry | Health Care Supplies |
| Founded / lineage | 1958 |
| S&P 500 addition date | 2016-09-23 |
| S&P 500 Equal Weight status | Current company constituent as of 2026-09-15 |
| Equal Weight target concept | Equal company weight at quarterly rebalance; nominally 0.20% when there are 500 companies |
| Canonical Swoopr company URL | /stocks/companies/cooper-companies/ |
What the Company Does
The most defensible high-level description of Cooper Companies begins with its GICS placement in Health Care Supplies. In practical terms, Cooper Companies participates in an industry where a company generally supplies equipment, devices, diagnostics, laboratory tools, consumables, or healthcare technology used in clinical care, research, or life-sciences workflows. That is an analytical starting point, not a substitute for Cooper Companies's own segment disclosure. The implementation should use the latest annual report to name the actual reported segments, economically important products and services, brands, customer groups, and geographies for Cooper Companies. Where Cooper Companies reports businesses that cross GICS boundaries, the page should preserve those distinctions instead of forcing every activity into the Health Care Supplies label. For users learning how to research Cooper Companies, the key question is: what operating activity causes a customer to pay the company? The answer should be expressed as a revenue tree rather than a marketing description. Start with the company's major reported business lines, connect each line to its paying customer, identify the unit that is sold or monetized, then identify whether the economics are recurring, transactional, cyclical, usage-based, regulated, project- based, volume-driven, or spread-driven for Cooper Companies. This turns a company description into a usable investment model.
How the Company Makes Money
For Cooper Companies, the primary business-model lens is a medical-device, diagnostics, life-science-tools, consumables, or healthcare-technology model. The variables that deserve the first pass are procedure volumes, instrument placements, consumable pull-through, installed-base growth, test volumes, new product launches, and research and healthcare budgets. These are not asserted as the company's reported KPIs; they are the industry mechanisms that should be mapped to the metrics Cooper Companies actually discloses. A strong implementation should show which mechanism drives each material revenue line, how pricing works, whether customer relationships repeat, and which revenue streams have materially different margin or capital characteristics for Cooper Companies. Revenue quality matters as much as revenue growth. When reviewing Cooper Companies, distinguish growth created by more customers or units from growth created by price, mix, acquisitions, foreign exchange, accounting presentation, or temporary industry conditions. Then ask whether incremental revenue requires proportional new capital, inventory, labor, marketing, or fixed assets for Cooper Companies. The answer determines whether growth can compound with attractive cash economics or whether growth itself consumes substantial capital for Cooper Companies.
Revenue Engine
For Cooper Companies, use the following operating variables as a compact revenue-engine checklist. Each item is an industry hypothesis that must be mapped to Cooper Companies's disclosed KPIs before publication.
- Procedure Volumes: test direction, cause, revenue sensitivity, margin effect, and whether the change is durable or cyclical.
- Instrument Placements: test direction, cause, revenue sensitivity, margin effect, and whether the change is durable or cyclical.
- Consumable Pull-Through: test direction, cause, revenue sensitivity, margin effect, and whether the change is durable or cyclical.
- Installed-Base Growth: test direction, cause, revenue sensitivity, margin effect, and whether the change is durable or cyclical.
- Test Volumes: test direction, cause, revenue sensitivity, margin effect, and whether the change is durable or cyclical.
- New Product Launches: test direction, cause, revenue sensitivity, margin effect, and whether the change is durable or cyclical.
Business Segments
Cooper Companies's exact segment names and reported segment financials must come from its latest filing. The production page should create one subsection per reportable segment and, for each, state what it sells, who buys it, how it is priced, its growth and margin characteristics, important geographies, strategic role, and specific risks for Cooper Companies. If management changes segment reporting, historical tables should preserve prior definitions and clearly mark the restatement boundary rather than splicing unlike periods together for Cooper Companies. Until the filing-derived segment table is populated, the investor should avoid treating the consolidated Health Care Supplies classification as if it described every activity. Cooper Companies may contain businesses with very different cyclicality and capital intensity. The highest-value segment analysis often comes from identifying which segment contributes disproportionate profit or cash flow, which segment consumes the most capital, and which segment carries the highest expectations for future growth for Cooper Companies.
Products, Services and Business Lines
The production dossier should inventory only economically significant Cooper Companies products, services, platforms, brands, or franchises. Each item should be tied to a reportable business line and a monetization mechanism for Cooper Companies. Avoid an exhaustive catalog copied from a corporate website. The useful questions are whether an offering is a gateway product, a recurring revenue source, a high-margin add-on, a regulated necessity, a commodity-like product, or a strategic product that influences customer retention elsewhere in the portfolio for Cooper Companies.
Customers and Buying Behavior
The relevant customer universe for this industry includes hospitals, laboratories, physicians, researchers, universities, biopharma companies, distributors, and patients depending on the product line. For Cooper Companies, the production version should identify which of those customer groups actually matter, whether a small number of customers represent concentration risk, how long purchasing decisions take, who controls the budget, and what makes a customer renew, reorder, switch, or delay purchases. Customer economics often explain why two companies in the same sub-industry can have very different margins and volatility for Cooper Companies. A durable customer relationship can show up through contracts, subscriptions, installed-base dependence, integration costs, distribution access, regulatory qualification, brand preference, or operational reliability for Cooper Companies. Those mechanisms must be evidenced for Cooper Companies; simply saying the company has “loyal customers” is not sufficient. The monitoring framework should watch for weakening retention, lower wallet share, rising incentives, longer sales cycles, or adverse changes in customer concentration for Cooper Companies.
Geographic Exposure
Do not infer Cooper Companies's geographic revenue from its headquarters. The latest 10-K should be used to populate revenue, assets, manufacturing, sourcing, regulatory exposure, and material customer exposure by geography when disclosed for Cooper Companies. Geography matters because foreign exchange, tariffs, export controls, taxes, local competition, political risk, and supply-chain concentration can change the economics even when consolidated demand is stable for Cooper Companies.
Business Model
Swoopr should connect Cooper Companies to the Business Model Atlas using a medical-device, diagnostics, life-science- tools, consumables, or healthcare-technology model as the initial classification, then refine it to the company’s actual mix. The business-model page should answer four linked questions: what scarce capability or asset Cooper Companies controls, what unit customers pay for, why customers choose or remain with the company, and what resources the company must continuously spend to protect that position. A business model is not merely a label; it is a causal explanation of how customer value becomes revenue, profit, and cash flow for Cooper Companies.
Company Economics
For a Health Care Supplies business, the core cost structure often includes R&D, manufacturing, quality systems, sales/service, regulatory compliance, and inventory. When reviewing Cooper Companies, separate fixed from variable costs and distinguish accounting expenses from cash investment. Then examine operating leverage: if revenue rises by 10%, which costs rise nearly in line, which lag, and which may step up after capacity thresholds for Cooper Companies? The same exercise should be repeated in reverse for a downturn because downside operating leverage is often more important than upside leverage for Cooper Companies. Capital intensity is equally important. Cooper Companies can report attractive operating margins while requiring large amounts of working capital, plant, equipment, acquired intangibles, capitalized software, regulatory capital, or other reinvestment. Cooper Companies's page should therefore reconcile earnings with cash generation and explain which investments are maintenance requirements versus discretionary growth spending.
Financial Statement Guide
Income statement
Start with the revenue lines and expense categories that reflect procedure volumes, instrument placements, and consumable pull-through. Separate organic operating change from acquisitions, divestitures, foreign exchange, accounting reclassifications, and unusual items for Cooper Companies. Margin analysis should show whether changes come from price, mix, volume, productivity, input costs, or overhead absorption for Cooper Companies.
Balance sheet
Identify the assets and liabilities that make the a medical-device, diagnostics, life-science-tools, consumables, or healthcare-technology model work. For Cooper Companies, focus on working capital, debt, goodwill and acquired intangibles, inventory or receivables where material, pension or insurance obligations where applicable, and any industry-specific capital or reserve requirements.
Cash flow statement
Reconcile reported earnings to operating cash flow and then to free cash flow after economically necessary capital expenditures for Cooper Companies. Watch working-capital swings, restructuring cash costs, acquisition spending, stock-based compensation, and other items that can make a single period look unusually strong or weak for Cooper Companies.
Capital expenditure and reinvestment
Determine how much spending merely maintains the existing earnings base and how much expands capacity or capabilities for Cooper Companies. The distinction is especially important when Cooper Companies's growth narrative depends on new facilities, networks, software, R&D, acquisitions, or customer acquisition.
Metrics That Matter Most
An initial industry-informed dashboard for Cooper Companies is below. Keep a metric only when Cooper Companies reports it consistently or it can be calculated reproducibly from filings.
| Metric | Why it matters | QA rule |
|---|
| Organic Revenue Growth | Connects the Health Care Supplies operating model to growth, margins, cash flow, or risk. | Preserve the company definition, source, period, and any methodology change. |
|---|
| Procedure/Test Volume | Connects the Health Care Supplies operating model to growth, margins, cash flow, or risk. | Preserve the company definition, source, period, and any methodology change. |
|---|
| Installed Base | Connects the Health Care Supplies operating model to growth, margins, cash flow, or risk. | Preserve the company definition, source, period, and any methodology change. |
|---|
| Consumables Mix | Connects the Health Care Supplies operating model to growth, margins, cash flow, or risk. | Preserve the company definition, source, period, and any methodology change. |
|---|
| Gross Margin | Connects the Health Care Supplies operating model to growth, margins, cash flow, or risk. | Preserve the company definition, source, period, and any methodology change. |
|---|
| R&D Intensity | Connects the Health Care Supplies operating model to growth, margins, cash flow, or risk. | Preserve the company definition, source, period, and any methodology change. |
|---|
| Backlog | Connects the Health Care Supplies operating model to growth, margins, cash flow, or risk. | Preserve the company definition, source, period, and any methodology change. |
|---|
| New-Product Contribution | Connects the Health Care Supplies operating model to growth, margins, cash flow, or risk. | Preserve the company definition, source, period, and any methodology change. |
|---|
| Free Cash Flow | Connects the Health Care Supplies operating model to growth, margins, cash flow, or risk. | Preserve the company definition, source, period, and any methodology change. |
|---|
| Regulatory Milestones | Connects the Health Care Supplies operating model to growth, margins, cash flow, or risk. | Preserve the company definition, source, period, and any methodology change. |
|---|
Competitive Position
Potential sources of competitive durability in this industry include clinical evidence, regulatory approvals, installed base, workflow integration, service networks, and switching costs. For Cooper Companies, each claimed advantage must be tied to evidence: better retention, structurally lower costs, stronger unit economics, sustained share, premium pricing, shorter payback, higher utilization, superior reliability, or another measurable outcome. A “moat” statement without a mechanism and observable consequence should not appear on the Cooper Companies production page. A useful starting peer set inside the current index is AbbVie, Abbott Laboratories, Agilent Technologies, Align Technology, Amgen, Baxter International. This is an index peer set, not a claim that every named company is a direct competitor in every product line for Cooper Companies. The final competitors section should distinguish direct product competitors, substitute technologies, vertically integrated customers/suppliers, and companies that compete primarily for capital or distribution for Cooper Companies.
Index peer comparison framework
| Peer | Why compare it | What to verify |
|---|
| AbbVie | Current S&P 500 peer classified in Biotechnology | Actual product overlap, customer overlap, margins, capital intensity, and geographic mix |
|---|
| Abbott Laboratories | Current S&P 500 peer classified in Health Care Equipment | Actual product overlap, customer overlap, margins, capital intensity, and geographic mix |
|---|
| Agilent Technologies | Current S&P 500 peer classified in Life Sciences Tools & Services | Actual product overlap, customer overlap, margins, capital intensity, and geographic mix |
|---|
| Align Technology | Current S&P 500 peer classified in Health Care Supplies | Actual product overlap, customer overlap, margins, capital intensity, and geographic mix |
|---|
| Amgen | Current S&P 500 peer classified in Biotechnology | Actual product overlap, customer overlap, margins, capital intensity, and geographic mix |
|---|
| Baxter International | Current S&P 500 peer classified in Health Care Equipment | Actual product overlap, customer overlap, margins, capital intensity, and geographic mix |
|---|
Industry Position
Cooper Companies should be analyzed inside the structure of the Health Care Supplies industry rather than in isolation. Map concentration, barriers to entry, buyer power, supplier power, substitution risk, capital requirements, regulation, technology change, and cyclicality for Cooper Companies. Then identify where Cooper Companies sits on the spectrum from price taker to differentiated supplier. This industry map is especially useful when Cooper Companies’s own results look strong: it helps determine whether the improvement reflects company-specific execution or a favorable cycle lifting most participants.
Supply Chain and Dependencies
An initial supply-chain map for this industry connects specialized components, contract manufacturers, regulators, distributors, and hospitals/labs/researchers. The production Cooper Companies page should identify material single- source dependencies, constrained inputs, outsourced manufacturing or service dependencies, logistics bottlenecks, regulated interfaces, and customer concentration. The strongest supply-chain analysis identifies not only who supplies whom but also where bargaining power sits and which participant absorbs volatility when supply or demand changes for Cooper Companies.
Economic Sensitivity
The macro variables most worth testing for this business model are healthcare utilization, hospital capital budgets, research funding, labor constraints, interest rates, and demographics. These are hypotheses, not a claim that every variable has equal influence on Cooper Companies. Link each selected indicator to a specific transmission mechanism - for example, higher rates changing financing costs, weaker employment changing demand or credit, or industrial production changing order volumes for Cooper Companies. Remove macro indicators that do not have a defensible causal path to Cooper Companies's economics.
Company History
Registry data records Cooper Companies's founding or corporate lineage as 1958 and its S&P 500 addition date as 2016-09-23. Those two dates are only anchors. A publishable history should be built from issuer and SEC sources and focus on events that changed the economic identity of Cooper Companies: founding, major product or market entries, mergers, divestitures, restructurings, leadership transitions, regulatory events, crises, and strategic pivots. Avoid trivia that does not explain today’s business.
Verified timeline anchors
- 1958: Founding or corporate-lineage date recorded in the constituent metadata source. Verify nuanced predecessor history against issuer materials.
- 2016-09-23: Cooper Companies security line
COOentered the S&P 500 according to the constituent registry used for this snapshot.
- 2026-09-15: Cooper Companies is treated as a current constituent company of the S&P 500 Equal Weight Index snapshot used by this package.
Capital Allocation
Evaluate Cooper Companies's capital allocation as a hierarchy: first the spending required to maintain the existing business; then high-return organic reinvestment; then strategic acquisitions or divestitures; then balance-sheet decisions; and finally dividends or repurchases. For this industry, Cooper Companies investors should pay particular attention to whether management is reinvesting during peaks in the cycle, paying too much for acquired growth, underfunding maintenance, or returning capital while leverage or other obligations remain elevated. The useful question is not whether Cooper Companies “returns cash to shareholders.” It is whether each dollar has been directed to its highest credible risk-adjusted use. Measure outcomes over multi-year periods using per-share results, returns on invested capital, cash conversion, balance-sheet resilience, and the performance of acquired or newly built assets for Cooper Companies. Repurchases can destroy value if executed at poor prices or merely offset heavy dilution for Cooper Companies.
Growth Drivers
Potential growth for Cooper Companies should be decomposed into observable mechanisms rather than summarized as a single forecast.
- Procedure Volumes: verify management evidence, identify the KPI, separate organic improvement from acquisition/price/mix, and define a disconfirming signal.
- Instrument Placements: verify management evidence, identify the KPI, separate organic improvement from acquisition/price/mix, and define a disconfirming signal.
- Consumable Pull-Through: verify management evidence, identify the KPI, separate organic improvement from acquisition/price/mix, and define a disconfirming signal.
- Installed-Base Growth: verify management evidence, identify the KPI, separate organic improvement from acquisition/price/mix, and define a disconfirming signal.
- Test Volumes: verify management evidence, identify the KPI, separate organic improvement from acquisition/price/mix, and define a disconfirming signal.
Risk Factors
Use Cooper Companies's current risk disclosures to decide which of the following industry risks actually deserve prominence. Each retained risk needs a causal path and a warning signal.
- Reimbursement Pressure: map the exposure to revenue, margin, cash flow, balance sheet, or strategic position; do not copy boilerplate risk language.
- Procedure Softness: map the exposure to revenue, margin, cash flow, balance sheet, or strategic position; do not copy boilerplate risk language.
- Product Recalls: map the exposure to revenue, margin, cash flow, balance sheet, or strategic position; do not copy boilerplate risk language.
- Regulatory Delays: map the exposure to revenue, margin, cash flow, balance sheet, or strategic position; do not copy boilerplate risk language.
- Hospital Budget Constraints: map the exposure to revenue, margin, cash flow, balance sheet, or strategic position; do not copy boilerplate risk language.
- New Technology: map the exposure to revenue, margin, cash flow, balance sheet, or strategic position; do not copy boilerplate risk language.
- Supply Shortages: map the exposure to revenue, margin, cash flow, balance sheet, or strategic position; do not copy boilerplate risk language.
Bull, Base and Bear Operating Framework
Bull operating case. A favorable fundamental path for Cooper Companies would combine healthy procedure volumes and instrument placements, stable or improving competitive position, disciplined reinvestment, and cost behavior that allows incremental revenue to convert efficiently into cash. This is not a share-price forecast. The purpose is to state what would have to go unusually well in the Cooper Companies business itself. Base operating case. A normal-execution path would show mixed but manageable movement in procedure volumes, instrument placements, and consumable pull-through, no material erosion in the company’s key competitive mechanisms, and capital allocation consistent with the economics of the business. Results may still be cyclical; “base” does not mean smooth. Bear operating case. A deteriorating path would combine one or more of reimbursement pressure, procedure softness, product recalls, and regulatory delays with weaker operating indicators, pressure on margins or cash conversion, and reduced strategic flexibility. The bear framework should be updated when new filings reveal a different risk concentration for Cooper Companies.
What Could Prove an Investment Thesis Wrong?
- Persistent deterioration in organic revenue growth. Define a numeric or filing-based threshold before relying on the thesis so the test is not moved after results disappoint.
- Weakening procedure volumes despite a healthy end market. Define a numeric or filing-based threshold before relying on the thesis so the test is not moved after results disappoint.
- Multi-period margin compression without a credible reinvestment explanation. Define a numeric or filing-based threshold before relying on the thesis so the test is not moved after results disappoint for Cooper Companies.
- Capital allocation that lowers per-share economics or raises balance-sheet risk. Define a numeric or filing-based threshold before relying on the thesis so the test is not moved after results disappoint for Cooper Companies.
- Evidence that customer switching costs, brand, network, cost position, or another claimed advantage is weaker than assumed. Define a numeric or filing-based threshold before relying on the thesis so the test is not moved after results disappoint for Cooper Companies.
- A structural industry change that makes historical comparisons misleading. Define a numeric or filing-based threshold before relying on the thesis so the test is not moved after results disappoint for Cooper Companies.
What Investors Commonly Misunderstand About This Company
- GICS classification is not the whole company. Cooper Companies is classified as Health Care Supplies, but actual segments may span adjacent markets. Use segment disclosures.
- Revenue growth is not automatically economic improvement. Price, mix, acquisitions, FX, and accounting changes can produce growth with very different cash consequences for Cooper Companies.
- The most visible product may not be the profit engine. Verify which Cooper Companies business lines produce operating profit and cash rather than assuming brand visibility equals economic importance.
- A strong cycle can masquerade as a stronger moat. Compare performance with peers and end-market conditions before attributing all improvement to execution for Cooper Companies.
- Free cash flow needs context. Working-capital timing, deferred investment, restructuring, and stock compensation can make one period unusually strong or weak for Cooper Companies.
What to Monitor
A practical Cooper Companies monitoring list should remain short enough to update every quarter. For each item, store the definition, historical series, source, and why a change would alter the Cooper Companies business thesis.
- Organic Revenue Growth: record trend, management explanation, link to revenue/margin/cash flow, and a threshold that would trigger deeper review.
- Procedure/Test Volume: record trend, management explanation, link to revenue/margin/cash flow, and a threshold that would trigger deeper review.
- Installed Base: record trend, management explanation, link to revenue/margin/cash flow, and a threshold that would trigger deeper review.
- Consumables Mix: record trend, management explanation, link to revenue/margin/cash flow, and a threshold that would trigger deeper review.
- Gross Margin: record trend, management explanation, link to revenue/margin/cash flow, and a threshold that would trigger deeper review for Cooper Companies.
- R&D Intensity: record trend, management explanation, link to revenue/margin/cash flow, and a threshold that would trigger deeper review.
- Backlog: record trend, management explanation, link to revenue/margin/cash flow, and a threshold that would trigger deeper review for Cooper Companies.
- Procedure Volumes: record trend, management explanation, link to revenue/margin/cash flow, and a threshold that would trigger deeper review.
- Instrument Placements: record trend, management explanation, link to revenue/margin/cash flow, and a threshold that would trigger deeper review.
- Consumable Pull-Through: record trend, management explanation, link to revenue/margin/cash flow, and a threshold that would trigger deeper review.
Questions Investors Should Ask
- What are Cooper Companies's actual reportable segments, and which segment contributes the most operating profit and cash?
- Which of procedure volumes, instrument placements, and consumable pull-through explains most of Cooper Companies's revenue change?
- Is Cooper Companies's pricing power strengthening, stable, or weakening, and what evidence proves it?
- How much of recent growth is organic versus acquisition, FX, price, mix, or accounting change for Cooper Companies?
- What portion of reinvestment is maintenance versus growth?
- Which customer group has the strongest bargaining power and why?
- Are customer concentration or supplier concentration becoming more material?
- Which metric would deteriorate first if the competitive position weakened?
- Does operating leverage improve cash economics in growth periods without creating excessive downside in contractions for Cooper Companies?
- What is the most important balance-sheet constraint on strategy?
- How has management allocated incremental cash over the last full cycle for Cooper Companies?
- Have acquisitions improved per-share economics after considering price paid and dilution for Cooper Companies?
- Which regulatory change would most directly alter the business model?
- What macro variable has the clearest causal link to demand or margins for Cooper Companies?
- What evidence would make the current business-model classification obsolete?
S&P 500 Equal Weight Index Context
As of the 2026-09-15 snapshot, Cooper Companies is one of 500 constituent companies represented by 503 security lines in the parent S&P 500 universe used by this package. The S&P 500 Equal Weight Index uses the same constituent companies but resets companies to equal weight at quarterly rebalances for Cooper Companies. With 500 companies, the nominal company target is about 0.20% immediately after a rebalance, before market movement causes weights to drift for Cooper Companies. Cooper Companies therefore has materially different index influence in the equal-weight version than it may have in the capitalization-weighted S&P 500.
Key Takeaways
- Cooper Companies is classified in Health Care / Health Care Supplies; use that classification as a starting point, not a replacement for segment research.
- The most useful operating variables to verify are procedure volumes, instrument placements, consumable pull-through, and installed-base growth.
- The cost structure should be analyzed around R&D, manufacturing, quality systems, and sales/service.
- The most relevant monitoring metrics begin with organic revenue growth, procedure/test volume, installed base, consumables mix, and gross margin.
- Industry risks include reimbursement pressure, procedure softness, product recalls, and regulatory delays, but only issuer-specific evidence should determine final risk ranking.
- Cash generation must be evaluated after maintenance reinvestment, working-capital needs, dilution, and acquisition spending for Cooper Companies.
- Cooper Companies receives the same nominal company weight as every other constituent at an S&P 500 Equal Weight quarterly reset, subject to multi-class allocation rules.
Frequently Asked Questions
What does Cooper Companies do?
Cooper Companies is classified by GICS in Health Care Supplies. That means the company participates in an industry where businesses generally supplies equipment, devices, diagnostics, laboratory tools, consumables, or healthcare technology used in clinical care, research, or life-sciences workflows. The final production description should use Cooper Companies’s latest filing to identify its exact segments, products, services, and customer groups.
How does Cooper Companies make money?
The primary analytical lens is a medical-device, diagnostics, life-science-tools, consumables, or healthcare-technology model. Investors should map Cooper Companies's actual disclosed revenue lines to procedure volumes, instrument placements, consumable pull-through, and installed-base growth and distinguish recurring, transactional, cyclical, regulated, or project-based economics as applicable.
What sector is Cooper Companies in?
Cooper Companies is classified in the Health Care sector and Health Care Supplies sub-industry in the constituent snapshot used by this package.
What metrics matter for Cooper Companies?
An initial industry-informed metric set includes organic revenue growth, procedure/test volume, installed base, consumables mix, gross margin, and R&D intensity. The production page should retain only metrics Cooper Companies reports consistently or that can be reliably calculated.
What are the main risks for Cooper Companies?
Industry-relevant risks include reimbursement pressure, procedure softness, product recalls, regulatory delays, and hospital budget constraints. The latest 10-K and 10-Q must be used to determine which risks are most material to Cooper Companies now.
Who are Cooper Companies's competitors?
Current index peers in the same or adjacent classification include AbbVie, Abbott Laboratories, Agilent Technologies, Align Technology, and Amgen. This is a research peer set, not a claim of direct competition across every product for Cooper Companies.
What economic conditions affect Cooper Companies?
The strongest macro hypotheses to test are healthcare utilization, hospital capital budgets, research funding, labor constraints, and interest rates. Each should be retained only when there is a clear transmission mechanism to demand, pricing, costs, financing, or capital allocation for Cooper Companies.
Is Cooper Companies in the S&P 500 Equal Weight Index?
Yes. Cooper Companies is treated as a current company constituent in the 2026-09-15 snapshot because the Equal Weight Index uses the same constituent companies as the S&P 500.
What is Cooper Companies's target weight in the Equal Weight Index?
At a quarterly reset, each constituent company is assigned an equal company weight for Cooper Companies. With 500 companies, the nominal target is about 0.20% per company before weights drift with market movements for Cooper Companies.
Does Cooper Companies have multiple share classes in the index?
No multi-class treatment is recorded for this issuer in the current snapshot; the package records security line COO.
How should an investor use this page?
Use the Cooper Companies dossier as an educational research map: identify the business model, verify the company-specific disclosures in primary sources, track a small set of causal operating metrics, and define thesis-breakers before relying on a conclusion.
Is this investment advice?
No. This dossier is educational research content. It does not provide individualized investment advice, a buy/sell recommendation, or a price target.
References
- U.S. Securities and Exchange Commission - Cooper Companies filings. https://www.sec.gov/edgar/browse/?CIK=711404&owner=exclude
Use the latest 10-K, 10-Q, 8-K, proxy statement, and applicable registration filings for company-specific operating facts.
- S&P Dow Jones Indices - S&P 500 Equal Weight Index. https://www.spglobal.com/spdji/en/indices/equity/sp-500-equal-weight-index/
Use for index identity and official index documentation.
- S&P Dow Jones Indices - U.S. Indices Methodology. https://www.spglobal.com/spdji/en/documents/methodologies/methodology-sp-us-indices.pdf
Use for equal-weight calculation, rebalancing, and multi-class treatment.
- Current constituent metadata snapshot used by this package. The package registry records ticker, GICS classification, CIK, founding/lineage field, and S&P 500 addition date as of 2026-09-15.
Editorial Verification Gate
Before this Cooper Companies dossier is marked GREEN, an editor or research agent must reconcile every issuer-specific narrative statement against the latest primary sources, populate actual segments and significant products, add current as-of-dated financial and operating metrics where useful, verify management and geography, expand the company timeline with sourced events, and replace any industry hypothesis that does not apply to the issuer. This gate is intentionally explicit: completeness of page structure must never be mistaken for verification of current financial facts.